Integrated Filing — IndAS



General information about company

Scrip Code 523642
NSE Symbol PIIND
MSEI Symbol NOTLISTED
ISIN INE603J01030
Name of company PI INDUSTRIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 04-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 27-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 04-11-2026   14:00:00
End date and time of board meeting 04-11-2026   19:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 1,70,180.00 3,40,410.00
Other income 6,110.00 12,520.00
Total income 1,76,290.00 3,52,930.00
2 Expenses
(a) Cost of materials consumed 78,970.00 1,47,160.00
(b) Purchases of stock-in-trade 7,490.00 11,720.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (460.00) 770.00
(d) Employee benefit expense 25,650.00 51,730.00
(e) Finance costs 840.00 1,630.00
(f) Depreciation, depletion and amortisation expense 10,490.00 20,860.00
(f) Other Expenses
1 Net impairment losses on financial assets 640.00 1,160.00
2 Power, Fuel & Water 9,150.00 17,140.00
3 Environment & Pollution Control Expenses 2,850.00 5,510.00
4 Freight & Cartage 2,290.00 3,750.00
5 Advertisement & Sales Promotion 2,870.00 5,230.00
6 Travelling and Conveyance 2,860.00 5,990.00
7 Legal & professional fees 2,590.00 5,460.00
8 Repairs & Maintenance 3,730.00 7,290.00
9 Laboratory & Testing Charges 1,370.00 2,940.00
10 Other expenses 6,910.00 14,550.00
Total other expenses 35,260.00 69,020.00
Total expenses 1,58,240.00 3,02,890.00
3 Total profit before exceptional items and tax 18,050.00 50,040.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 18,050.00 50,040.00
6 Tax expense
7 Current tax 4,540.00 11,840.00
8 Deferred tax 1,640.00 2,100.00
9 Total tax expenses 6,180.00 13,940.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 11,870.00 36,100.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 350.00 540.00
16 Total profit (loss) for period 12,220.00 36,640.00
17 Other comprehensive income net of taxes 1,670.00 4,870.00
18 Total Comprehensive Income for the period 13,890.00 41,510.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 13,890.00 41,510.00
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,520.00 1,520.00
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 8.05 24.15
Diluted earnings (loss) per share from continuing operations 8.05 24.15
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 8.05 24.15
Diluted earnings (loss) per share from continuing and discontinued operations 8.05 24.15
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes: 1 The above consolidated unaudited financial results were reviewed and recommended by the Audit Committee of the Company and approved by the Board of Directors at their meeting held on November 04, 2026. 2 The consolidated financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. 3 The consolidated financial results include the results of the following entities namely, Parent Company - PI Industries Limited; Subsidiaries (including step down subsidiaries): (a) PI Health Sciences Limited (b) PI Health Sciences USA, LLC (c) PI Health Sciences Netherlands BV (d) Archimica S.p.A Italy (e) PI AgSciences Limited (Formerly known as Plant Health Care limited) (f) PI AgSciences, Inc. (Formerly known as Plant Health Care, Inc, Nevada) (g) PI AgSciencies, S. de R.L. de C.V. (Formerly known as Plant Health Care de Mexico S. de R.L. de C.V.) (h) PI AgSciences (UK) Limited (Formerly known as Plant Health Care (UK) Limited) (i) PI AgSciences Spain, S.A (Formerly known as Plant Health Care Espa�a) (j) PI AgSciences Brasil Ltda (Formerly know as Plant Health Care Insumos Agricolas LTDA) (k) Jivagro Limited (l) PI Life Science Research Limited (m) PI Flowtech B.V. (n) PI Industries Management Consultancies LLC Dubai (o) PI Innoventures Limited (Formerly known as PILL Finance and Investments Limited) (p) PI Japan Co. Limited (q) PI Bioferma Private Limited (r) PI Fermachem Private Limited ; Controlled trust - PII ESOP Trust; Joint Venture - PI Kumiai Private Limited (including its subsidiary - Kumiai Chemical Industry (India) Private Limited (w.e.f July 03, 2026)) ; Associate - Solinnos Agro Sciences Private Limited. 4 a) In April 2023, PI Health Sciences Limited (PIHS), a wholly owned subsidiary of the Company acquired 100% equity of Solis Pharmachem Private Limited and Therachem Research Medilab (India) Private Limited and specific assets of Therachem Research Medilab LLC, USA. The purchase consideration for the above included contingent consideration to be paid over a period of 6 years subject to achievement of specified business performance and to support for business development activities. Considering the performance of the acquired business since the acquisition, and the successful establishment of an experienced in-house global business development team, no longer requiring external business development support, the Company renegotiated a mutually beneficial one-time settlement payment with erstwhile owners. This settlement resulted in a write-back of the contingent consideration of Rs. 1,260 million, which was presented under Exceptional Items during the year ended March 31, 2026. b) Pursuant to the notification of the 'New Labour Codes' as issued in November 2025, the Group reassessed its employee benefit obligations in accordance with the revised definition of wages and accordingly, an incremental liability of Rs. 229 million had been disclosed as an Exceptional Item during the year ended March 31, 2026. 5 Segment information as per Ind AS 108 Operating Segments is as per Annexure I. Place: Mumbai For PI Industries Limited Date: November 04, 2026 Regd. Office: Udaisagar Road, Udaipur - 313001 (Raj) Mayank Singhal Phone: 0294 2492451-55 Fax: 0294 2491946 Vice Chairperson & Managing Director CIN: L24211RJ1946PLC000469 DIN: 00006651



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 3,75,650.00
Capital work-in-progress 99,870.00
Investment property 0.00
Goodwill 60,670.00
Other intangible assets 37,560.00
Intangible assets under development 27,700.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 3,690.00
Non-current financial assets
Non-current investments 6,320.00
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Other Financial Assets 2,340.00
Total of other non-current financial assets 2,340.00
Total non-current financial assets 8,660.00
Deferred tax assets (net) 2,930.00
Other non-current assets
1 Other non-current assets 9,410.00
Total of other non-current assets 9,410.00
Total non-current assets 6,26,140.00
2 Current assets
Inventories 1,22,350.00
Current financial asset
Current investments 2,02,680.00
Trade receivables, current 2,17,630.00
Cash and cash equivalents 32,940.00
Bank balance other than cash and cash equivalents 1,39,160.00
Loans, current 90.00
Other current financial assets
Total of other current financial assets 2,200.00
Total current financial assets 5,94,700.00
Current tax assets (net) 1,570.00
Other current assets
1 Other current assets 41,820.00
Total of other current assets 41,820.00
Total current assets 7,60,440.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 13,86,580.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,520.00
Other equity 11,44,220.00
Total equity attributable to owners of parent 11,45,740.00
Non controlling interest 0.00
Total equity 11,45,740.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 13,790.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 6,900.00
2 Other financial liabilities 10,050.00
Total of other non-current financial liabilities 16,950.00
Total non-current financial liabilities 30,740.00
Provisions, non-current 3,230.00
Deferred tax liabilities (net) 9,560.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 43,530.00
Current liabilities
Current financial liabilities
Borrowings, current 6,960.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 7,370.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1,06,130.00
Total Trade payable 1,13,500.00
Other current financial liabilities
1 Lease liabilities 2,310.00
2 Other current financial liabilities 55,970.00
Total of other current financial liabilities 58,280.00
Total current financial liabilities 1,78,740.00
Other current liabilities 10,610.00
1 Other current liabilities 10,610.00
Total of other current liabilities 10,610.00
Provisions, current 4,240.00
Current tax liabilities (Net) 3,720.00
Deferred government grants, Current 0.00
Total current liabilities 1,97,310.00
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 2,40,840.00
Total equity and liabilites 13,86,580.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Agro Chemicals 1,62,800.00 3,27,680.00
2 Pharma 7,590.00 13,010.00
3 Inter Segment adjustment 0.00 0.00
Total Segment Revenue 1,70,390.00 3,40,690.00
Less: Inter segment revenue 210.00 280.00
Revenue from operations 1,70,180.00 3,40,410.00
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Agro Chemicals 24,730.00 63,080.00
2 Pharma (6,010.00) (14,170.00)
3 Inter Segment adjustment (320.00) 1,670.00
Total Profit before tax 18,400.00 50,580.00
i. Finance cost 0.00 0.00
ii. Other Unallocable Expenditure net off Unallocable income 0.00 0.00
Profit before tax 18,400.00 50,580.00
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Agro Chemicals 12,42,440.00 12,42,440.00
2 Pharma 1,44,140.00 1,44,140.00
3 Inter Segment adjustment 0.00 0.00
Total Segment Asset 13,86,580.00 13,86,580.00
Un-allocable Assets 0.00 0.00
Net Segment Asset 13,86,580.00 13,86,580.00
4 Segment Liabilities
Segment Liabilities
1 Agro Chemicals 2,06,480.00 2,06,480.00
2 Pharma 34,360.00 34,360.00
3 Inter Segment adjustment 0.00 0.00
Total Segment Liabilities 2,40,840.00 2,40,840.00
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 2,40,840.00 2,40,840.00
Disclosure of notes on segments Textual Information(2)



Text Block

Textual Information(2) Note: The business of the group is divided into two segments as below: a) Agro chemicals - Agro chemicals includes Agchem export (CSM), Domestic Agri Brands and Biologicals. b) Pharma - Pharma comprises contract research and development, contract development and manufacturing of active, key starting materials and intermediates used in pharmaceutical industry.



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurements gain/(loss) on defined benefits plans 200.00 290.00
Total Amount of items that will not be reclassified to profit and loss 200.00 290.00
2 Income tax relating to items that will not be reclassified to profit or loss 50.00 100.00
3 Amount of items that will be reclassified to profit and loss
1 Effective portion of gain/(loss) on cash flow hedges 690.00 6,400.00
2 Exchange difference on translation of foreign operations 1,060.00 510.00
Total Amount of items that will be reclassified to profit and loss 1,750.00 6,910.00
4 Income tax relating to items that will be reclassified to profit or loss 230.00 2,230.00
5 Total Other comprehensive income 1,670.00 4,870.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 50,040.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1,630.00
Adjustments for decrease (increase) in inventories (410.00)
Adjustments for decrease (increase) in trade receivables, current 10,960.00
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (650.00)
Adjustments for decrease (increase) in other non-current assets (570.00)
Adjustments for other financial assets, non-current (60.00)
Adjustments for other financial assets, current 1,950.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 14,950.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 790.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 20,860.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 190.00
Adjustments for other financial liabilities, current 6,830.00
Adjustments for other financial liabilities, non-current 200.00
Adjustments for unrealised foreign exchange losses gains 1,640.00
Adjustments for dividend income 0.00
Adjustments for interest income 8,180.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (3,780.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 70.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 1,510.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 47,930.00
Net cash flows from (used in) operations 97,970.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 8,980.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 88,990.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 290.00
Purchase of property, plant and equipment 65,520.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 8,180.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (3,830.00)
Net cash flows from (used in) investing activities (60,880.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 5,420.00
Repayments of borrowings 9,920.00
Payments of lease liabilities 1,750.00
Dividends paid 15,170.00
Interest paid 1,630.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (23,050.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 5,060.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents (450.00)
Net increase (decrease) in cash and cash equivalents 4,610.00
Cash and cash equivalents cash flow statement at beginning of period 28,330.00
Cash and cash equivalents cash flow statement at end of period 32,940.00